[go: up one dir, main page]

HK1049155B - 用作腺苷受體對抗劑的聚環烷基嘌呤 - Google Patents

用作腺苷受體對抗劑的聚環烷基嘌呤

Info

Publication number
HK1049155B
HK1049155B HK02109310.2A HK02109310A HK1049155B HK 1049155 B HK1049155 B HK 1049155B HK 02109310 A HK02109310 A HK 02109310A HK 1049155 B HK1049155 B HK 1049155B
Authority
HK
Hong Kong
Prior art keywords
polycycloalkylpurines
receptor antagonists
adenosine receptor
adenosine
disorders
Prior art date
Application number
HK02109310.2A
Other languages
English (en)
Other versions
HK1049155A1 (en
Inventor
William F Kiesman
James E Dowling
Carol L Ensinger
Gnanasambandam Kumaravel
Russell C Petter
Ko Chung Lin
He Xi Chang
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1049155A1 publication Critical patent/HK1049155A1/xx
Publication of HK1049155B publication Critical patent/HK1049155B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK02109310.2A 1999-11-12 2002-12-23 用作腺苷受體對抗劑的聚環烷基嘌呤 HK1049155B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16519199P 1999-11-12 1999-11-12
PCT/US2000/031058 WO2001034610A1 (en) 1999-11-12 2000-11-13 Polycycloalkylpurines as adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
HK1049155A1 HK1049155A1 (en) 2003-05-02
HK1049155B true HK1049155B (zh) 2009-11-06

Family

ID=22597852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02109310.2A HK1049155B (zh) 1999-11-12 2002-12-23 用作腺苷受體對抗劑的聚環烷基嘌呤

Country Status (35)

Country Link
US (5) US6649600B1 (zh)
EP (3) EP1230243B1 (zh)
JP (1) JP2003513982A (zh)
KR (2) KR20080027971A (zh)
CN (2) CN100390178C (zh)
AT (1) ATE424403T1 (zh)
AU (1) AU784556B2 (zh)
BG (1) BG65720B1 (zh)
BR (1) BR0015545A (zh)
CA (1) CA2390496A1 (zh)
CY (1) CY1110512T1 (zh)
CZ (1) CZ20021614A3 (zh)
DE (1) DE60041710D1 (zh)
DK (1) DK1230243T3 (zh)
EA (1) EA005211B1 (zh)
EE (1) EE05365B1 (zh)
ES (1) ES2323357T3 (zh)
GE (1) GEP20043303B (zh)
HK (1) HK1049155B (zh)
IL (1) IL149487A0 (zh)
IS (1) IS6379A (zh)
ME (1) MEP42208A (zh)
MX (1) MXPA02004796A (zh)
NO (1) NO328956B1 (zh)
NZ (2) NZ527917A (zh)
PL (1) PL206890B1 (zh)
PT (1) PT1230243E (zh)
RS (1) RS50381B (zh)
SI (1) SI1230243T1 (zh)
SK (1) SK287311B6 (zh)
TR (1) TR200201260T2 (zh)
TW (1) TWI272270B (zh)
UA (1) UA77391C2 (zh)
WO (1) WO2001034610A1 (zh)
ZA (1) ZA200203701B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
HUP0203371A3 (en) * 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE10145193C1 (de) 2001-09-13 2003-03-13 Sachtler Gmbh & Co Kg Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
UA84404C2 (ru) * 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
RU2367442C2 (ru) * 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
JP4859666B2 (ja) 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
MX2007015863A (es) * 2005-06-17 2008-04-02 Apogee Biotechnology Corp Inhibidores de esfingosina cinasa.
WO2007059330A2 (en) * 2005-11-17 2007-05-24 Medkura Inc. Cubane nucleoside analogs
US20070238672A1 (en) * 2006-04-06 2007-10-11 Howard Dittrich Co-administration of adenosine a1 receptor antagonists and anticonvulsants
CN101085785B (zh) * 2006-06-06 2011-09-21 中国科学院上海药物研究所 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
WO2007149366A1 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2008011054A2 (en) * 2006-07-17 2008-01-24 Tyratech, Inc. Compositions and methods for controlling insects
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
WO2009152458A1 (en) * 2008-06-13 2009-12-17 Biogen Idec Ma Inc. Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en) 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
EP3121208A1 (en) * 2009-12-04 2017-01-25 Commonwealth Scientific and Industrial Research Organisation Polymeric materials
CN101709034B (zh) * 2009-12-14 2017-05-31 大连九信精细化工有限公司 双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
TWI538905B (zh) * 2010-12-22 2016-06-21 Ｈ 朗德貝克公司 雙環［３．２．１］辛基醯胺衍生物及其用途
US20140243302A1 (en) 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
JP2016516708A (ja) * 2013-03-14 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビシクロ［２．２．２］酸のｇｐｒ１２０モジュレーター
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US10633315B2 (en) 2016-10-19 2020-04-28 Eastman Chemical Company Synthesis of bicyclo[2.2.2]octanes
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
MX2020002944A (es) 2017-09-14 2020-09-28 Daiichi Sankyo Co Ltd Compuesto que tiene estructura ciclica.
WO2019075004A1 (en) 2017-10-11 2019-04-18 Eastman Chemical Company SYNTHESIS OF BICYCLO [2.2.2] OCTANE DERIVATIVES
US10730863B2 (en) 2017-11-01 2020-08-04 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid X receptor modulators
CN113366000A (zh) 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
US10836899B2 (en) 2018-12-13 2020-11-17 Eastman Chemical Company Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011399A1 (en) 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5270316A (en) 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
JPH04270222A (ja) * 1991-02-25 1992-09-25 Kyowa Hakko Kogyo Co Ltd 脳機能改善剤
JPH04346986A (ja) * 1991-05-23 1992-12-02 Kyowa Hakko Kogyo Co Ltd トリチウム標識化されたキサンチン誘導体
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
JP3115128B2 (ja) * 1991-11-08 2000-12-04 協和醗酵工業株式会社 キサンチン誘導体
JPH05294966A (ja) * 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
JPH0616668A (ja) * 1992-03-12 1994-01-25 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (zh) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5384176A (en) * 1992-12-11 1995-01-24 Zimmerman; Richard C. Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675498A (en) * 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
AU7675598A (en) * 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Hepatic edema remedy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU3757999A (en) 1998-04-24 1999-11-16 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
ATE358484T1 (de) 1998-07-02 2007-04-15 Kyowa Hakko Kogyo Kk Antidiabetische medikamente
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
HUP0203371A3 (en) * 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DK1781657T3 (da) * 2004-02-14 2013-06-10 Glaxosmithkline Ip Dev Ltd Medikamenter med hm74a-receptor aktivitet

Also Published As

Publication number Publication date
KR20020049050A (ko) 2002-06-24
US20060252730A1 (en) 2006-11-09
NO20022238L (no) 2002-07-12
ZA200203701B (en) 2004-02-23
EP1230243B1 (en) 2009-03-04
EE200200247A (et) 2003-06-16
PT1230243E (pt) 2009-06-12
NO20022238D0 (no) 2002-05-10
BR0015545A (pt) 2002-08-06
AU1600001A (en) 2001-06-06
WO2001034610A1 (en) 2001-05-17
CN1402729A (zh) 2003-03-12
DE60041710D1 (de) 2009-04-16
ATE424403T1 (de) 2009-03-15
UA77391C2 (en) 2006-12-15
NZ527917A (en) 2005-03-24
US6649600B1 (en) 2003-11-18
CN101255162A (zh) 2008-09-03
EE05365B1 (et) 2010-12-15
MXPA02004796A (es) 2007-01-30
KR100863761B1 (ko) 2008-10-16
SK287311B6 (sk) 2010-06-07
TR200201260T2 (tr) 2002-09-23
BG65720B1 (bg) 2009-08-31
NZ519426A (en) 2003-08-29
EP2305684A1 (en) 2011-04-06
HK1049155A1 (en) 2003-05-02
US20070015732A1 (en) 2007-01-18
AU784556B2 (en) 2006-05-04
IS6379A (is) 2002-05-10
US7579354B2 (en) 2009-08-25
TWI272270B (en) 2007-02-01
YU33802A (sh) 2006-01-16
RS50381B (sr) 2009-11-10
MEP42208A (en) 2011-02-10
CA2390496A1 (en) 2001-05-17
SI1230243T1 (sl) 2009-08-31
EA200200560A1 (ru) 2002-10-31
IL149487A0 (en) 2002-11-10
PL356033A1 (en) 2004-06-14
KR20080027971A (ko) 2008-03-28
PL206890B1 (pl) 2010-10-29
BG106762A (en) 2003-01-31
US20090221821A1 (en) 2009-09-03
CY1110512T1 (el) 2015-04-29
NO328956B1 (no) 2010-06-28
CN100390178C (zh) 2008-05-28
EP2070930A1 (en) 2009-06-17
GEP20043303B (en) 2004-01-12
EA005211B1 (ru) 2004-12-30
CZ20021614A3 (cs) 2002-07-17
JP2003513982A (ja) 2003-04-15
DK1230243T3 (da) 2009-06-15
SK6632002A3 (en) 2003-02-04
ES2323357T3 (es) 2009-07-14
US20040067966A1 (en) 2004-04-08
EP1230243A1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
HK1049155A1 (en) Polycycloalkylpurines as adenosine receptor antagonists
ZA200203702B (en) Adenosine receptor antagonists and methods of making and using the same.
HK1083838A1 (en) A2a adenosine receptor antagonists
HK1085724A1 (en) 3,6-disubstituted azabicyclo 3.1.0-hexane derivatives as muscarinic receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
GB9815618D0 (en) Treatment of dyskinesia
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121113